Study guide
4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
EDAIC Part I European Diploma in Anaesthesiology and Intensive Care
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The EDAIC Part I Examination
1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy
2 Chapter 2: Anatomy for Anaesthesia and Intensive Care
2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart
3 Chapter 3: Respiratory and Cardiovascular Physiology
3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics
4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
5 Chapter 5: Endocrine and Haematological Physiology
5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric
6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation
7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics
7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity
8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics
8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents
9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics
9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy
10 Chapter 10: Haematological and Internal Medicine Pharmacology
10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions
11 Chapter 11: Physics, Clinical Measurement and Medical Equipment
11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring
12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis
12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units
13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal
13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)
14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management
14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
15 Chapter 15: Coexisting Disease and Preoperative Investigations
15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia
16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury
17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia
17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia
18 Chapter 18: Anaesthetic Complications and Specialty Settings
18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery
19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management
19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support
20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes
21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics
23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration
24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies
24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy
25 Chapter 25: Burns, Environmental Emergencies and Patient Transport
25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill
4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
Key Takeaways Explain This Topic AI
Arterial pH is maintained between 7.35 and 7.45 ( [ H + ] ≈ 35 – 45 nmol/L [H^+] \approx 35\text{--}45\text{ nmol/L} [ H + ] ≈ 35 – 45 nmol/L ), governed in traditional physiology by the Henderson-Hasselbalch relationship with a carbonic acid p K a pK_a p K a of 6.1.
The bicarbonate buffer system provides the principal extracellular buffering capacity because it operates as an open system where C O 2 CO_2 C O 2 is vented by the lungs and HCO 3 − \text{HCO}_3^- HCO 3 − is reclaimed and generated by the kidneys.
Expected respiratory compensation in metabolic acidosis is quantified by Winter's formula: P a CO 2 = ( 1.5 × [ HCO 3 − ] ) + 8 ± 2 mmHg P_a\text{CO}_2 = (1.5 \times [\text{HCO}_3^-]) + 8 \pm 2\text{ mmHg} P a CO 2 = ( 1.5 × [ HCO 3 − ]) + 8 ± 2 mmHg ; failure to reach this value indicates a concomitant respiratory acid-base disorder.
The serum anion gap must be adjusted for hypoalbuminemia by subtracting ~2.5 mEq/L from the expected normal gap for every 10 g/L (1 g/dL) decline in serum albumin below 40 g/L.
Under Stewart physical-chemical physiology, [ H + ] [H^+] [ H + ] is a dependent variable dictated by three independent variables: Strong Ion Difference ( S I D SID S I D ), total non-volatile weak acids ( A tot A_{\text{tot}} A tot ), and P CO 2 P\text{CO}_2 P CO 2 ; large-volume 0.9% normal saline ( S I D = 0 SID = 0 S I D = 0 ) dilutes plasma S I D SID S I D (~40 mEq/L), precipitating hyperchloremic metabolic acidosis.
Last updated: October 2026
4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
Acid-base regulation is vital for maintaining cellular enzyme kinetics, cardiac inotropy, systemic vascular tone, and membrane electrophysiology. Anaesthesiologists and intensivists must master both the classical Henderson-Hasselbalch framework and Peter Stewart's quantitative physical-chemical methodology to diagnose complex mixed acid-base abnormalities and guide fluid resuscitation.
- 1. Quantitative Foundations of Acid-Base Balance
- The Nanomolar Reality of Hydrogen Ions
In healthy arterial blood, the physiological pH range is 7.35 to 7.45 , corresponding to a hydrogen ion concentration ( [ H + ] [H^+] [ H + ] ) of 35 to 45 nmol/L :
[ H + ] = 10 ( 9 − p H ) ⟹ At pH 7.40, [ H + ] = 40 nmol/L [H^+] = 10^{(9 - pH)}\quad \implies \quad \text{At pH 7.40, } [H^+] = 40\text{ nmol/L} [ H + ] = 1 0 ( 9 − p H ) ⟹ At pH 7.40, [ H + ] = 40 nmol/L
Notice the vast concentration disparity: [ H + ] [H^+] [ H + ] is measured in nanomoles per liter ( 10 − 9 mol/L 10^{-9}\text{ mol/L} 1 0 − 9 mol/L ) , whereas major extracellular electrolytes ( [ Na + ] , [ Cl − ] , [ HCO 3 − ] [\text{Na}^+], [\text{Cl}^-], [\text{HCO}_3^-] [ Na + ] , [ Cl − ] , [ HCO 3 − ] ) are measured in millimoles per liter ( 10 − 3 mol/L 10^{-3}\text{ mol/L} 1 0 − 3 mol/L ) —a difference of six orders of magnitude ( 10 6 10^6 1 0 6 ). Because hydrogen ion concentrations are minuscule, minor absolute shifts profoundly alter protein charge distribution, enzyme tertiary conformation, and cellular receptor affinity.
The Henderson-Hasselbalch Formulation
The classical model characterizes acid-base balance through the hydration of carbon dioxide and dissociation of carbonic acid:
C O 2 + H 2 O ⇌ Carbonic Anhydrase H 2 C O 3 ⇌ H + + HCO 3 − CO_2 + H_2O \xrightleftharpoons{\text{Carbonic Anhydrase}} H_2CO_3 \xrightleftharpoons{} H^+ + \text{HCO}_3^- C O 2 + H 2 O Carbonic Anhydrase H 2 C O 3 H + + HCO 3 −
Applying the law of mass action yields the Henderson-Hasselbalch equation:
p H = p K a + log 10 ( [ HCO 3 − ] α × P a CO 2 ) pH = pK_a + \log_{10}\left(\frac{[\text{HCO}_3^-]}{\alpha \times P_a\text{CO}_2}\right) p H = p K a + lo g 10 ( α × P a CO 2 [ HCO 3 − ] )
Where:
p K a = 6.10 pK_a = 6.10 p K a = 6.10 for the carbonic acid/bicarbonate system at 37°C.
α = 0.03 mmol/L/mmHg \alpha = 0.03\text{ mmol/L/mmHg} α = 0.03 mmol/L/mmHg (or 0.225 mmol/L/kPa 0.225\text{ mmol/L/kPa} 0.225 mmol/L/kPa ), the solubility coefficient of C O 2 CO_2 C O 2 in plasma at 37°C.
At normal values ( [ HCO 3 − ] = 24 mmol/L [\text{HCO}_3^-] = 24\text{ mmol/L} [ HCO 3 − ] = 24 mmol/L and P a CO 2 = 40 mmHg P_a\text{CO}_2 = 40\text{ mmHg} P a CO 2 = 40 mmHg ):
p H = 6.10 + log 10 ( 24 0.03 × 40 ) = 6.10 + log 10 ( 24 1.2 ) = 6.10 + log 10 ( 20 ) = 6.10 + 1.30 = 7.40 pH = 6.10 + \log_{10}\left(\frac{24}{0.03 \times 40}\right) = 6.10 + \log_{10}\left(\frac{24}{1.2}\right) = 6.10 + \log_{10}(20) = 6.10 + 1.30 = 7.40 p H = 6.10 + lo g 10 ( 0.03 × 40 24 ) = 6.10 + lo g 10 ( 1.2 24 ) = 6.10 + lo g 10 ( 20 ) = 6.10 + 1.30 = 7.40
2. Physiological Buffering Systems: Open vs Closed Systems
A chemical buffer consists of a weak acid and its conjugate base. Buffering capacity is maximized when environmental pH equals the buffer's p K a pK_a p K a .
The Isohydric Principle
All buffer pairs present within a shared aqueous compartment are in simultaneous equilibrium with the identical free [ H + ] [H^+] [ H + ] :
[ H + ] = K 1 [ H A 1 ] [ A 1 − ] = K 2 [ H A 2 ] [ A 2 − ] = K 3 [ H A 3 ] [ A 3 − ] [H^+] = K_1 \frac{[HA_1]}{[A_1^-]} = K_2 \frac{[HA_2]}{[A_2^-]} = K_3 \frac{[HA_3]}{[A_3^-]} [ H + ] = K 1 [ A 1 − ] [ H A 1 ] = K 2 [ A 2 − ] [ H A 2 ] = K 3 [ A 3 − ] [ H A 3 ]
The Bicarbonate Buffer System: An Open System
The carbonic acid/bicarbonate pair is the most powerful extracellular buffer. Despite having an apparent p K a pK_a p K a of 6.10 (which is far from physiological pH 7.40 and would yield poor buffering in a closed container), it has immense buffering capacity in vivo because it is an open physiological system :
The acidic component ( C O 2 CO_2 C O 2 ) is continuously excreted across the alveolar-capillary membrane by the respiratory system .
The basic component ( [ HCO 3 − ] [\text{HCO}_3^-] [ HCO 3 − ] ) is independently regulated, conserved, and synthesized by the renal tubules .
Non-Bicarbonate Buffers: Closed Systems
Non-bicarbonate buffers operate in closed biological compartments:
Haemoglobin (~80% of non-bicarbonate buffering in whole blood): Haemoglobin is rich in histidine residues containing imidazole side chains ( p K a ≈ 6.8 pK_a \approx 6.8 p K a ≈ 6.8 ). Deoxygenated haemoglobin is a weaker acid (and stronger base) than oxyhaemoglobin ( the Haldane effect ). As venous blood desaturates in peripheral tissues, deoxyhaemoglobin directly binds protons generated by C O 2 CO_2 C O 2 hydration without altering local pH.
Plasma Proteins (mainly Albumin): Plasma proteins possess multiple histidine residues that buffer hydrogen ions in the intravascular space.
Inorganic Phosphates ( H P O 4 2 − / H 2 P O 4 − HPO_4^{2-} / H_2PO_4^- H P O 4 2 − / H 2 P O 4 − , p K a = 6.8 pK_a = 6.8 p K a = 6.8 ): Serves as an important intracellular buffer and forms the primary titratable acid buffer in renal tubular fluid.
Bone Carbonate and Calcium Phosphate: In severe chronic metabolic acidosis, bone mineral acts as a massive proton sink, exchanging Ca 2 + \text{Ca}^{2+} Ca 2 + and Na + \text{Na}^+ Na + for H + H^+ H + , which leads to bone demineralization and hypercalciuria.
3. Traditional Diagnostic Approach: Primary Disorders and Compensation
When a primary disturbance occurs, the body initiates secondary physiological compensation to return the [ HCO 3 − ] / P a CO 2 [\text{HCO}_3^-] / P_a\text{CO}_2 [ HCO 3 − ] / P a CO 2 ratio toward 20:1. The respiratory system responds within minutes, whereas renal compensation requires 24 to 72 hours.
Primary Disorder Primary Abnormality Secondary Compensation Quantitative Compensatory Expected Rules
Metabolic Acidosis ↓ [ HCO 3 − ] \downarrow [\text{HCO}_3^-] ↓ [ HCO 3 − ] Hyperventilation → ↓ P a CO 2 \rightarrow \downarrow P_a\text{CO}_2 →↓ P a CO 2 Winter's Formula: P a CO 2 = ( 1.5 × [ HCO 3 − ] ) + 8 ± 2 mmHg P_a\text{CO}_2 = (1.5 \times [\text{HCO}_3^-]) + 8 \pm 2\text{ mmHg} P a CO 2 = ( 1.5 × [ HCO 3 − ]) + 8 ± 2 mmHg
Metabolic Alkalosis ↑ [ HCO 3 − ] \uparrow [\text{HCO}_3^-] ↑ [ HCO 3 − ] Hypoventilation → ↑ P a CO 2 \rightarrow \uparrow P_a\text{CO}_2 →↑ P a CO 2 P a CO 2 P_a\text{CO}_2 P a CO 2 rises 0.7 mmHg per 1 mEq/L rise in [ HCO 3 − ] [\text{HCO}_3^-] [ HCO 3 − ] (capped at ~55–60 mmHg by hypoxia)
Acute Resp. Acidosis ↑ P a CO 2 \uparrow P_a\text{CO}_2 ↑ P a CO 2 Tissue/RBC buffering [ HCO 3 − ] [\text{HCO}_3^-] [ HCO 3 − ] rises 1 mEq/L per 10 mmHg rise in P a CO 2 P_a\text{CO}_2 P a CO 2 above 40 mmHg
Chronic Resp. Acidosis ↑ P a CO 2 \uparrow P_a\text{CO}_2 ↑ P a CO 2 Renal H + H^+ H + excretion [ HCO 3 − ] [\text{HCO}_3^-] [ HCO 3 − ] rises 3.5 to 4 mEq/L per 10 mmHg rise in P a CO 2 P_a\text{CO}_2 P a CO 2 above 40 mmHg
Acute Resp. Alkalosis ↓ P a CO 2 \downarrow P_a\text{CO}_2 ↓ P a CO 2 Tissue buffering [ HCO 3 − ] [\text{HCO}_3^-] [ HCO 3 − ] falls 2 mEq/L per 10 mmHg fall in P a CO 2 P_a\text{CO}_2 P a CO 2 below 40 mmHg
Chronic Resp. Alkalosis ↓ P a CO 2 \downarrow P_a\text{CO}_2 ↓ P a CO 2 Renal HCO 3 − \text{HCO}_3^- HCO 3 − wasting [ HCO 3 − ] [\text{HCO}_3^-] [ HCO 3 − ] falls 4 to 5 mEq/L per 10 mmHg fall in P a CO 2 P_a\text{CO}_2 P a CO 2 below 40 mmHg
Standard Base Excess (SBE)
Base excess represents the quantity of strong acid or base required to titrate 1 liter of fully oxygenated blood back to pH 7.40 at P CO 2 = 40 mmHg P\text{CO}_2 = 40\text{ mmHg} P CO 2 = 40 mmHg at 37°C. Standard Base Excess (SBE) standardizes this measurement to in vivo extracellular fluid by setting haemoglobin to 5 g/dL , eliminating artifactual respiratory shifts. Normal SBE is − 2 to + 2 mEq/L -2\text{ to }+2\text{ mEq/L} − 2 to + 2 mEq/L . A negative SBE indicates base deficit (metabolic acidosis).
- 4. The Anion Gap and Etiological Differentiation
- Serum Anion Gap (AG)
Based on the principle of electrical neutrality, total serum cations must equal total anions. The classical Anion Gap measures the difference between commonly measured cations and anions:
AG = [ Na + ] − ( [ Cl − ] + [ HCO 3 − ] ) \text{AG} = [\text{Na}^+] - ([\text{Cl}^-] + [\text{HCO}_3^-]) AG = [ Na + ] − ([ Cl − ] + [ HCO 3 − ])
Normal Reference Range: 8 to 12 mEq/L (or 10 to 14 mEq/L if potassium is included: [ Na + + K + ] − [ Cl − + HCO 3 − ] [\text{Na}^+ + \text{K}^+] - [\text{Cl}^- + \text{HCO}_3^-] [ Na + + K + ] − [ Cl − + HCO 3 − ] ).
Unmeasured physiological anions include albumin (~75%), phosphate, sulfate, and organic acids.
Hypoalbuminemia and Anion Gap Correction
Serum albumin is the predominant unmeasured anion. At pH 7.40, each 1 g/dL (10 g/L) of albumin carries approximately 2.5 mEq/L of negative charge:
Corrected AG = Observed AG + 2.5 × ( 4.0 − Albumin in g/dL ) \text{Corrected AG} = \text{Observed AG} + 2.5 \times (4.0 - \text{Albumin in g/dL}) Corrected AG = Observed AG + 2.5 × ( 4.0 − Albumin in g/dL )
Corrected AG = Observed AG + 0.25 × ( 40 − Albumin in g/L ) \text{Corrected AG} = \text{Observed AG} + 0.25 \times (40 - \text{Albumin in g/L}) Corrected AG = Observed AG + 0.25 × ( 40 − Albumin in g/L )
Clinical Trap: In critically ill patients with severe hypoalbuminemia (e.g., serum albumin 1.5 g/dL), baseline normal AG is only 12 − ( 2.5 × 2.5 ) ≈ 6 mEq/L 12 - (2.5 \times 2.5) \approx 6\text{ mEq/L} 12 − ( 2.5 × 2.5 ) ≈ 6 mEq/L . An observed AG of 12 mEq/L in this patient actually represents a corrected AG of 18 mEq/L , concealing an occult high anion gap metabolic acidosis.
High Anion Gap Metabolic Acidosis (HAGMA): GOLDMARK
Caused by accumulation of unmeasured organic or exogenous acids:
G: Glycols (ethylene glycol → \rightarrow → glycolate and oxalate crystals; propylene glycol)
O: Oxoproline (5-oxoproline / pyroglutamic acid; triggered by chronic paracetamol ingestions in depleted glutathione states)
L: L-Lactate (Type A tissue hypoperfusion, shock, sepsis; Type B biguanides, liver failure, mitochondrial toxicity)
- D: D-Lactate (short bowel syndrome; bacterial carbohydrate fermentation)
- M: Methanol (formic acid accumulation; optic disc hyperemia and blindness)
A: Aspirin (Salicylates) (uncouples oxidative phosphorylation; causes mixed primary respiratory alkalosis and HAGMA)
- R: Renal Failure / Uremia (impaired excretion of inorganic sulfates, phosphates, and hippurate)
- K: Ketoacidosis (diabetic, alcoholic, starvation; accumulation of acetoacetate and β \beta β -hydroxybutyrate)
- Normal Anion Gap Metabolic Acidosis (NAGMA / Hyperchloremic Acidosis)
Characterized by a reciprocal rise in serum chloride ( [ Cl − ] [\text{Cl}^-] [ Cl − ] ) as bicarbonate is lost:
Gastrointestinal bicarbonate loss: Severe diarrhea, biliary or pancreatic fistulas, surgical diversion (ureterosigmoidostomy).
Renal tubular acidosis (RTA):
Type 1 (Distal): Failure of intercalated cells to secrete H + H^+ H + (urine pH remains > 5.5 >5.5 > 5.5 despite systemic acidemia; associated with hypokalemia and nephrocalcinosis).
Type 2 (Proximal): Impaired reabsorption of HCO 3 − \text{HCO}_3^- HCO 3 − in proximal tubule (associated with Fanconi syndrome).
Type 4 (Hyperkalemic): Aldosterone deficiency or resistance in collecting duct principal cells (hypoaldosteronism).
Iatrogenic: Massive volume resuscitation with 0.9% Normal Saline .
5. The Stewart Modern Physical-Chemical Approach
In the 1980s, Canadian physiologist Peter Stewart revolutionized acid-base theory by demonstrating that [ H + ] [H^+] [ H + ] and [ HCO 3 − ] [\text{HCO}_3^-] [ HCO 3 − ] are dependent variables . They cannot change on their own. Instead, their concentrations are mathematically determined by three independent variables obeying two fundamental physical-chemical laws: electrical neutrality and conservation of mass .
The Three Independent Variables
P CO 2 P\text{CO}_2 P CO 2 : The respiratory independent variable, governed by alveolar ventilation and metabolic C O 2 CO_2 C O 2 production.
Strong Ion Difference ( S I D SID S I D ): The net charge difference between all fully dissociated, non-reacting strong cations and strong anions:
S I D = ( [ Na + ] + [ K + ] + [ Ca 2 + ] + [ Mg 2 + ] ) − ( [ Cl − ] + [ Lactate − ] + [ Other strong anions − ] ) SID = ([\text{Na}^+] + [\text{K}^+] + [\text{Ca}^{2+}] + [\text{Mg}^{2+}]) - ([\text{Cl}^-] + [\text{Lactate}^-] + [\text{Other strong anions}^-]) S I D = ([ Na + ] + [ K + ] + [ Ca 2 + ] + [ Mg 2 + ]) − ([ Cl − ] + [ Lactate − ] + [ Other strong anions − ])
Normal Apparent SID ( S I D a SID_a S I D a ): 40 to 42 mEq/L in arterial blood.
Mechanism: Water is an infinite reservoir of H + H^+ H + and O H − OH^- O H − ( H 2 O ⇌ H + + O H − H_2O \rightleftharpoons H^+ + OH^- H 2 O ⇌ H + + O H − ). To satisfy electrical neutrality, if S I D SID S I D decreases ( < 40 mEq/L <40\text{ mEq/L} < 40 mEq/L , meaning strong anions are increased relative to cations), water must dissociate to generate free H + H^+ H + ions → \rightarrow → Strong Ion Acidosis . Conversely, if S I D SID S I D increases ( > 42 mEq/L >42\text{ mEq/L} > 42 mEq/L ), water dissociation is suppressed and H + H^+ H + is consumed → \rightarrow → Strong Ion Alkalosis .
Total Non-Volatile Weak Acids ( A tot A_{\text{tot}} A tot ):
Represents the sum of all circulating weak non-volatile acids ( H A ⇌ H + + A − HA \rightleftharpoons H^+ + A^- H A ⇌ H + + A − ), primarily serum albumin and inorganic phosphate .
Albumin acts as a weak polyanion at physiological pH. A reduction in albumin ( hypoalbuminemia ) decreases A tot A_{\text{tot}} A tot , which exerts an alkalinizing effect on plasma. Hyperalbuminemia (severe dehydration) exerts an acidifying effect . Stewart Physical-Chemical Model
- =================================================================
- INDEPENDENT VARIABLES DEPENDENT VARIABLES
- -------------------- -------------------
- 1. PCO2 (Ventilation) ====> - [H+] and pH
- 2. SID (Strong Ion Difference) ====> - [HCO3-]
- 3. Atot (Albumin & Phosphate) ====> - [CO3 2-], [OH-], [A-]
- =================================================================
Rule: To change [H+] or [HCO3-], at least ONE independent variable MUST change!
Effective SID ( S I D e SID_e S I D e ) and the Strong Ion Gap ( S I G SIG S I G )
To determine whether unmeasured anions exist without relying on the albumin-vulnerable traditional anion gap, Stewart formulated the Effective SID ( S I D e SID_e S I D e ) :
S I D e = [ HCO 3 − ] + [ Albumin − ] + [ Phosphate − ] SID_e = [\text{HCO}_3^-] + [\text{Albumin}^-] + [\text{Phosphate}^-] S I D e = [ HCO 3 − ] + [ Albumin − ] + [ Phosphate − ]
Strong Ion Gap (SIG) = S I D a − S I D e \text{Strong Ion Gap (SIG)} = SID_a - SID_e Strong Ion Gap (SIG) = S I D a − S I D e
In normal healthy plasma, all charges balance, and S I G ≈ 0 mEq/L SIG \approx 0\text{ mEq/L} S I G ≈ 0 mEq/L .
A positive S I G SIG S I G ( > 2 mEq/L > 2\text{ mEq/L} > 2 mEq/L ) indicates the presence of unmeasured strong anions (ketoacids, toxic metabolites, sulfate). Unlike the traditional anion gap, S I G SIG S I G is mathematically corrected for changes in albumin and phosphate.
6. Intravenous Crystalloids Through the Stewart Lens
Stewart physical-chemical physiology provides the definitive scientific explanation for why large-volume intravenous crystalloids alter acid-base balance.
Crystalloid Solution [ Na + ] [\text{Na}^+] [ Na + ] [ Cl − ] [\text{Cl}^-] [ Cl − ] Other Strong Ions Buffer Anion In Vivo SID Clinical Acid-Base Consequence
0.9% Normal Saline 154 154 None None 0 mEq/L Hyperchloremic Metabolic Acidosis (dilutes plasma S I D SID S I D from 40 toward 0)
Hartmann's Solution 131 111 K + 5 , Ca 2 + 2 \text{K}^+ 5, \text{Ca}^{2+} 2 K + 5 , Ca 2 + 2 Lactate 29 ~28 mEq/L Acid-Base Neutral (in vivo lactate metabolized to C O 2 / H 2 O CO_2/H_2O C O 2 / H 2 O )
Plasma-Lyte 148 140 98 K + 5 , Mg 2 + 1.5 \text{K}^+ 5, \text{Mg}^{2+} 1.5 K + 5 , Mg 2 + 1.5 Acetate 27, Gluconate 23 ~50 mEq/L Mild Alkalinizing Effect (acetate/gluconate metabolized in muscle/liver)
The Pathophysiology of 0.9% Saline-Induced Hyperchloremic Acidosis
In a bag of 0.9% NaCl, [ Na + ] = 154 mmol/L [\text{Na}^+] = 154\text{ mmol/L} [ Na + ] = 154 mmol/L and [ Cl − ] = 154 mmol/L [\text{Cl}^-] = 154\text{ mmol/L} [ Cl − ] = 154 mmol/L . The S I D SID S I D of 0.9% saline is:
S I D Saline = 154 − 154 = 0 mEq/L SID_{\text{Saline}} = 154 - 154 = 0\text{ mEq/L} S I D Saline = 154 − 154 = 0 mEq/L
Normal human plasma has a S I D a ≈ 40 mEq/L SID_a \approx 40\text{ mEq/L} S I D a ≈ 40 mEq/L with a chloride concentration of ~100–104 mmol/L. When large volumes of 0.9% NaCl are infused, the excess exogenous chloride disproportionately raises serum [ Cl − ] [\text{Cl}^-] [ Cl − ] relative to [ Na + ] [\text{Na}^+] [ Na + ] , driving the plasma S I D SID S I D downward from 40 toward 0 mEq/L.
As plasma S I D SID S I D shrinks, water molecules must dissociate ( H 2 O → H + + O H − H_2O \rightarrow H^+ + OH^- H 2 O → H + + O H − ) to balance the excess strong anions, generating free hydrogen ions and causing dilutional hyperchloremic metabolic acidosis .
In contrast, balanced crystalloids (e.g., Plasma-Lyte, Hartmann's) contain physiological chloride levels (~98–111 mmol/L) balanced by metabolizable organic anions (lactate, acetate, gluconate). Once infused, these organic anions are oxidized to C O 2 CO_2 C O 2 and water by hepatic and peripheral tissues, leaving behind their accompanying sodium cations. This maintains plasma S I D SID S I D around 40 mEq/L and prevents metabolic acidosis.